FDA Delays Cause Drug Cost Spikes Last Updated: April 26, 2017
Filed under:
Print Friendly, PDF & Email

HFMA: Mike Alkire: In March, the House Energy & Commerce Committee held a hearing to examine the state of generic drugs and determine whether slow new drug approvals contribute to higher pricing. At the hearing, the Food and Drug Administration (FDA) pointed to market forces, not regulatory hurdles, as causing limited competition and subsequent high prices. Although market forces are part of the story, the FDA should assume some responsibility and work to become a more nimble organization that can help unleash greater competition in the market.

Full story